Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Since then, the demand for hematology testing has evolved, with greater focus on automation of manual processes and streamlining workflow, expanding the utility of hematological parameters so as to support diagnosis, monitoring and treatment across disease areas, beyond routine testing. In 2018, Roche and Sysmex entered into a non-exclusive collaboration agreement to offer Total Laboratory Solutions (TLS). This allows customers who want to purchase products for clinical chemistry, immunochemistry, and hematology testing from one vendor to do so seamlessly with Roche and Sysmex.

The GBP sees the introduction of an IT Solutions Collaboration Agreement. In the newly defined collaboration, the two companies have agreed to utilize their respective IT platforms to improve customer experience, in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making. The GBP agreement will allow Roche and Sysmex to deliver tailored hematology solutions to new and existing customers, while having the benefits of working with a single provider. The partnership will also strive to develop a joint framework to ensure and promote connectivity through standardization of cybersecurity measures. The GBP agreement will run until the end of 2030.

“Roche is committed to supporting improvements in hematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anemia and leukemia,” said Thomas Schinecker, CEO Roche Diagnostics. “Extending our longstanding partnership with Sysmex underscores our unique synergy and our objective to offer our customers high-quality hematology solutions to improve the testing efficiency in central laboratories in hospitals and commercial laboratories, ultimately benefiting the millions of patients living with blood disorders.”


Related Links:
Roche
Sysmex